DXVX Redefines Identity as Vaccine and Platform Company Through R&D Commercialization

DXVX announced on May 28 that, as expectations rise for research and development achievements such as licensing out its technology assets, the company is redefining its identity from a genome diagnostics company to a bio-healthcare company.

This year, DXVX is conducting step-by-step negotiations for licensing out its major technology assets?including its ultra-long-term room-temperature storage mRNA vaccine platform, an oral obesity treatment, and the OVM-200 cancer vaccine?with large domestic and international pharmaceutical and biotech companies. The company has recently entered the final stages of technology transfer, including negotiations for material transfer agreements (MTAs) with major domestic and global pharmaceutical giants, and is expecting visible results within this year.

In particular, for its platform technologies, DXVX can sign license-out agreements with multiple companies that require the technology, allowing for an expansion of commercialization opportunities. In addition to its current negotiation partners, DXVX plans to continuously seek additional partners to further commercialize its technologies.

The oral obesity treatment has completed preparations for global technology validation by filing two patents for candidate substances and is undergoing further development. The OVM-200 cancer vaccine has secured R&D and commercialization rights in Korea, China (including Hong Kong, Macau, and Taiwan), and India.

Additional pipeline development is also progressing smoothly. DXVX has completed a substance patent application for its mRNA cancer vaccine, and is achieving results in the microbiome sector by securing anti-obesity strains, microbiome strains for alleviating depression, and developing healthcare products.

DXVX is also developing technologies to prepare for Disease X, a potentially fatal disease such as the recently resurging coronavirus, which could reemerge at any time. At the end of last year, the company secured universal coronavirus vaccine and therapeutic technologies from Stanford University and LucaAIcell in the United States, and is preparing for further research and development.

DXVX expects that, in addition to the pipelines currently being promoted for licensing out, ongoing R&D of various technology assets will lead to long-term achievements as a vaccine and platform technology development company.

A DXVX representative stated, "The high level of global interest in our diverse pipelines is now leading to progress in the licensing-out process, so we expect visible achievements this year," adding, "This year will be a time for us to redefine our identity as a bio-healthcare company developing vaccine and platform technologies."